🔴 Ironwood Pharmaceuticals is trading 6% down in pre-market; no clear catalyst identified

Ironwood Pharmaceuticals is trading 5.81% down at $3.89, with no clear company-specific catalyst identified for August 25, 2026.

• Ironwood raised 2026 revenue guidance on August 6; its latest SEC filing was also dated August 6.
• The broader market is modestly higher, making a market-wide explanation unlikely.
• Recheck for delayed filings, analyst actions, or overnight headlines.